Logo image of CRGX

CARGO THERAPEUTICS INC (CRGX) Stock Fundamental Analysis

USA - NASDAQ:CRGX - US14179K1016 - Common Stock

4.47 USD
-0.07 (-1.54%)
Last: 8/18/2025, 9:25:47 PM
4.47 USD
0 (0%)
After Hours: 8/18/2025, 9:25:47 PM
Fundamental Rating

3

Taking everything into account, CRGX scores 3 out of 10 in our fundamental rating. CRGX was compared to 534 industry peers in the Biotechnology industry. While CRGX has a great health rating, there are worries on its profitability. CRGX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRGX has reported negative net income.
In the past year CRGX has reported a negative cash flow from operations.
CRGX Yearly Net Income VS EBIT VS OCF VS FCFCRGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of CRGX (-85.76%) is worse than 71.14% of its industry peers.
CRGX's Return On Equity of -93.30% is in line compared to the rest of the industry. CRGX outperforms 47.61% of its industry peers.
Industry RankSector Rank
ROA -85.76%
ROE -93.3%
ROIC N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRGX Yearly ROA, ROE, ROICCRGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

CRGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRGX Yearly Profit, Operating, Gross MarginsCRGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

CRGX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRGX Yearly Shares OutstandingCRGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
CRGX Yearly Total Debt VS Total AssetsCRGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

CRGX has an Altman-Z score of 2.91. This is not the best score and indicates that CRGX is in the grey zone with still only limited risk for bankruptcy at the moment.
CRGX has a better Altman-Z score (2.91) than 71.69% of its industry peers.
There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.91
ROIC/WACCN/A
WACCN/A
CRGX Yearly LT Debt VS Equity VS FCFCRGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 12.37 indicates that CRGX has no problem at all paying its short term obligations.
The Current ratio of CRGX (12.37) is better than 85.48% of its industry peers.
A Quick Ratio of 12.37 indicates that CRGX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 12.37, CRGX belongs to the top of the industry, outperforming 85.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.37
Quick Ratio 12.37
CRGX Yearly Current Assets VS Current LiabilitesCRGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

CRGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.79%, which is quite impressive.
EPS 1Y (TTM)92.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CRGX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.88% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.22%
EPS Next 2Y13.77%
EPS Next 3Y12.68%
EPS Next 5Y5.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRGX Yearly Revenue VS EstimatesCRGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M
CRGX Yearly EPS VS EstimatesCRGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRGX Price Earnings VS Forward Price EarningsCRGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRGX Per share dataCRGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as CRGX's earnings are expected to grow with 12.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.77%
EPS Next 3Y12.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARGO THERAPEUTICS INC

NASDAQ:CRGX (8/18/2025, 9:25:47 PM)

After market: 4.47 0 (0%)

4.47

-0.07 (-1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-10 2025-11-10
Inst Owners98.83%
Inst Owner Change-0.01%
Ins Owners0.35%
Ins Owner Change-5.13%
Market Cap216.17M
Revenue(TTM)N/A
Net Income(TTM)-221778000
Analysts49.09
Price Target5.61 (25.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.97%
Min EPS beat(2)-65.12%
Max EPS beat(2)-6.83%
EPS beat(4)2
Avg EPS beat(4)-11.28%
Min EPS beat(4)-65.12%
Max EPS beat(4)23.75%
EPS beat(8)4
Avg EPS beat(8)-199.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.13%
PT rev (3m)-48.48%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)-16.77%
EPS NY rev (1m)-2.34%
EPS NY rev (3m)-6.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-3.66
EYN/A
EPS(NY)-2.62
Fwd EYN/A
FCF(TTM)-3.97
FCFYN/A
OCF(TTM)-3.92
OCFYN/A
SpS0
BVpS4.92
TBVpS4.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.76%
ROE -93.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.37
Quick Ratio 12.37
Altman-Z 2.91
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)322.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.96%
EPS Next Y21.22%
EPS Next 2Y13.77%
EPS Next 3Y12.68%
EPS Next 5Y5.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-266.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-288.58%
OCF growth 3YN/A
OCF growth 5YN/A

CARGO THERAPEUTICS INC / CRGX FAQ

What is the ChartMill fundamental rating of CARGO THERAPEUTICS INC (CRGX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRGX.


Can you provide the valuation status for CARGO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CARGO THERAPEUTICS INC (CRGX). This can be considered as Overvalued.


Can you provide the profitability details for CARGO THERAPEUTICS INC?

CARGO THERAPEUTICS INC (CRGX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CARGO THERAPEUTICS INC?

The Earnings per Share (EPS) of CARGO THERAPEUTICS INC (CRGX) is expected to grow by 21.22% in the next year.